This invention is directed to a method of treating drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine or a pharmaceutically acceptable salt and/or solvate thereof at a dosage that provides a therapeutic serum concentration. In one embodiment, the average serum concentration is 50 ng/mL to 180 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds, and preferably about 30 milliseconds.
